Biotech firm Moderna recently announced that it would never enforce the patent on its COVID-19 vaccine in 92 countries currently receiving the shots through a global program. It’s the first major pharmaceutical company to announce such a move, which critics say came later than it should have and which opens the door to wide-scale global production. Under CEO Stéphane Bancel, Moderna is also developing mRNA vaccines targeting 15 pathogens that are more common in the developing world, as well as longtime public-health threats such as influenza and RSV.
A weekly newsletter featuring conversations with the world’s top CEOs, managers, and founders. Join the Leadership Brief.
More Must-Read Stories From TIME
- Supreme Court Overturns Roe v. Wade, Undoing Constitutional Right to Abortion
- What the Supreme Court’s Abortion Decision Means for Your State
- The Failure of the Feminist Industrial Complex
- The Fight Over Abortion Has Only Just Begun
- Column: How Stereotypes Shape the Language People Use
- Everything We Know About Beyoncé's New Album, Renaissance
- Homes Made from Straw or Fungi Can Now Get You a Cheaper Mortgage in the Netherlands
- Going on Vacation This Summer? Welcome to the 'Revenge Travel' Economy
